British Journal of Clinical Pharmacology

Proceedings of the Dutch Society for Clinical Pharmacology and Biopharmacy: 8 October 2001
pp. 543P-543P(1)

Bioanalysis of the novel peptide anticancer drug kahalalide F in human plasma by h.p.l.c. under basic conditions coupled with positive turbo-ionspray tandem mass spectrometry
pp. 543P-543P(1)
Authors: Stokvis, E.; Rosing, H.; López-Lázaro, L.; Jimeno, J. M.; Supko, J. G.; Schellens, J. H. M.; Beijnen, J. H.

Population pharmacokinetics of intranasally administered low dose melatonin
pp. 543P-544P(2)
Authors: Helfrich, E.; Neef, C.; Merkus, F. W. H. M.

Bisphosphonate (olpadronate) retention and its determinants in Paget's disease of bone
pp. 544P-545P(2)
Authors: Cremers, S.; Eekhoff, E.; Dam, S. v.; den Hartigh, J.; Hamdy, H.; Vermeij, P.; Papapoulos, S.

Does the change of omeprazole to pantoprazole affect clozapine plasma concentrations?
pp. 545P-545P(1)
Authors: Mookhoek, E. J.; Loonen, A. J. M.

Adenosine-5′-triphosphate opens potassium channels in the forearm vascular bed
pp. 545P-546P(2)
Authors: Verkaik, N. J.; van Ginneken, E. E. M.; Smits, P.; Rongen, G. A.

6-Thioguanine in azathioprine and 6-mercaptopurine intolerant patients with inflammatory bowel disease
pp. 546P-547P(2)
Authors: Derijks, L. J. J.; de Jong, D. J.; Gilissen, L. P. L.; Engels, L. G. J. B.; Mulder, C. J. J.; Bos, L. P.; Lohman, J. J. H. M.; Hooymans, P. M.

Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin
pp. 547P-547P(1)
Authors: Dingemanse, J.; Schaarschmidt, D.; van Giersbergen, P. L. M.

The effectiveness of HMG-CoA reductase inhibitors in an elderly population is independent of apolipoprotein E-genotypes
pp. 548P-548P(1)
Authors: Maitland-van der Zee, Anke-Hilse; Stricker, Bruno H. CH.; Klungel, Olaf H.; Kastelein, John J. P.; Hofman, Albert; Leufkens, Hubertus G. M.; van Broeckhoven, Christine; van Duijn, Cornelia M.; de Boer, Anthonius

Baseline function of placental vascular K_ATP-channels in healthy and in diabetic women
pp. 548P-549P(2)
Authors: Bisseling, T. M.; Steegers, E. A. P.; Wouterse, A. C.; Elving, L.; Russel, F. G. M.; Smits, P.

The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus; a systematic review
pp. 549P-550P(2)
Authors: Wulffelé, M. G.; Kooy, A.; de Zeeuw, D.; Stehouwer, C. D. A.; Gansevoort, R. T.

The prevalence of CYP2C19 genotypes in a population of healthy Dutch volunteers and apparent gender differences in phenotypes
pp. 550P-550P(1)
Authors: Tamminga, Wim J.; Wemer, Johan; Oosterhuis, Berend; de Zeeuw, Rokus A.; de Leij, Lou F. M. H.; Jonkman, Jan H. G.

The clinical relevance of routine genotyping of CYP2D6/2C19 null alleles of psychiatric patients
pp. 550P-551P(2)
Authors: de Vries, E. M.; Pot, H. J.; Conemans, J. M. H.; Uges, D. R. A.

Use of antipsychotics in Parkinson's disease in daily practice
pp. 551P-551P(1)
Authors: van de Vijver, D. A. M. C.; Roos, R. A. C.; Jansen, P. A. F.; Porsius, A. J.; de Boer, A.

Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals
pp. 552P-552P(1)
Authors: de Maat, M. M. R.; Huitema, A. D. R.; Mulder, J. W.; Meenhorst, P. L.; van Gorp, E. C. M.; Beijnen, J. H.

A population pharmacokinetic model for Cremophor EL using nonlinear mixed-effect modeling: model building and validation
pp. 552P-553P(2)
Authors: van den Bongard, H. J. G. D.; Mathôt, R. A. A.; van Tellingen, O.; Schellens, J. H. M.; Beijnen, J. H.

Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of the novel anticancer agent E7070 in four phase I studies
pp. 553P-553P(1)
Authors: van Kesteren, CH.; Mathôt, R. A. A.; Raymond, E.; Armand, J. P.; Dittrich, CH.; Dumez, H.; Roché, H.; Droz, J. P.; Punt, C.; Ravic, M.; Wanders, J.; Beijnen, J. H.; Fumoleau, P.; Schellens, J. H. M.

Evaluation of prediction of tacrolimus area under the curve by trough concentrations
pp. 554P-554P(1)
Authors: Stolk, L. M. L.; van Duijnhoven, E. M.; Christiaans, M. H. L.; van Hooff, J. P.

Plasma pharmacokinetics of [¹¹C]-flumazenil and its major metabolite [¹¹C]-flumazenil `acid'
pp. 554P-555P(2)
Authors: Franssen, E. J. F.; Greuter, H. N. J. M.; Touw, D. J.; Luurtsema, G.; Windhorst, A. D.; Lammertsma, A. A.

Interaction between sotalol and albuterol after CABG: influence on postoperative arrhythmias and length of stay at an intensive care unit
pp. 555P-556P(2)
Authors: Vader, C.; Grouls, R.; van Gerven, A.; Ackerman, E.; Korsten, H.; Schönberger, J.; ter Woorst, F.; Botman, C.; Leufkens, H.

Pharmacodynamic effects of albuterol nebulization in hospitalized COPD-patients because of an exacerbation with blocked gastrointestinal absorption
pp. 556P-556P(1)
Authors: Cromheecke, H.; Grouls, R.; Creemers, J.; Smeenk, F.; Verboom, L.; Ackerman, E.

Failure of prescribers to adjust antibiotic dose to impaired renal function in daily clinical practice
pp. 557P-557P(1)
Authors: Vogtländer, N. P. J.; van Kasteren, M. E. F.; Natsch, S.; Kullberg, B. J.; Hekster, Y. A.; van der Meer, J. W. M.

Determinants of undertreatment of hypercholesterolaemia in a population-based study in The netherlands
pp. 557P-558P(2)
Authors: Mantel-Teeuwisse, A. K.; Verschuren, W. M. M.; Klungel, O. H.; Porsius, A. J.; de Boer, A.

Evaluation of the use of a medication database as a tool for detecting drug interactions
pp. 558P-558P(1)
Authors: Spaans, E.; Jansen, P. A. F.

Epidemiological evaluation of hospital prescribing concurrence with pharmacotherapeutic guidelines on infectious diseases
pp. 559P-559P(1)
Authors: Fijn, R.; Chow, M. C.; Schuur, P. M. H.; de Jong-van den Berg, L. T. W.; Brouwers, J. R. B. J.

Lead poisoning: case studies
pp. 451-458(8)
Authors: Gordon, J. N.; Taylor, A.; Bennett, P. N.

Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials
pp. 459-468(10)
Authors: Nguyen, Laurent; Tranchand, Brigitte; Puozzo, Christian; Variol, Philippe

Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice
pp. 469-473(5)
Authors: Sturrock, N. D. C.; Lannon, B.; Fay, T. N.

Pharmacokinetic/pharmacodynamic model for prednisolone inhibition of whole blood lymphocyte proliferation
pp. 474-484(11)
Authors: Magee, Mindy He; Blum, Robert A.; Lates, Christian D.; Jusko, William J.

Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin
pp. 485-491(7)
Authors: Dingemanse, Jasper; Meyerhoff, Carsten; Schadrack, Jan

Dose-finding and efficacy study for i.m. artemotil (beta-arteether) and comparison with i.m. artemether in acute uncomplicated P. falciparum malaria
pp. 492-500(9)
Authors: Looareesuwan, S.; Oosterhuis, B.; Schilizzi, B. M.; Sollie, F. A. E.; Wilairatana, P.; Krudsood, S.; Lugt, Ch. B.; Peeters, P. A. M.; Peggins, J. O.

Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers
pp. 501-507(7)
Authors: Knoester, P. D.; Jonker, D. M.; van der Hoeven, R. T. M.; Vermeij, T. A. C.; Edelbroek, P. M.; Brekelmans, G. J.; de Haan, G. J.

Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients
pp. 508-518(11)
Authors: Danesi, Romano; Innocenti, Federico; Fogli, Stefano; Gennari, Alessandra; Baldini, Editta; Di Paolo, Antonello; Salvadori, Barbara; Bocci, Guido; Conte, Pier Franco; Del Tacca, Mario

The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine
pp. 519-525(7)
Authors: Yasuda, Sally Usdin; Zannikos, Peter; Young, Andrea E.; Fried, Karen M.; Wainer, Irving W.; Woosley, Raymond L.

MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine
pp. 526-534(9)
Authors: Drescher, Siegfried; Schaeffeler, Elke; Hitzl, Monika; Hofmann, Ute; Schwab, Matthias; Brinkmann, Ulrich; Eichelbaum, Michel; Fromm, Martin F.

Concomitant overdosing of other drugs in patients with paracetamol poisoning
pp. 535-541(7)
Authors: Schmidt, Lars E.; Dalhoff, Kim

Antiviral agents: advances and problems
pp. 542-542(1)